Hangzhou Healthytide Biotechnology

Hangzhou Healthytide Biotechnology (also known as Hetai Jianyu) is an innovative Chinese biotechnology company founded in 2021 that specializes in the discovery and development of targeted peptide-based therapeutics and radiopharmaceuticals. The company leverages its proprietary Novotide high-throughput polypeptide screening platform and a diverse single-molecule peptide library to identify novel targeting ligands. Healthytide's pipeline focuses on targeted peptide receptor-mediated radionuclide therapy (PRRT) and peptide-drug conjugates (PDCs) for oncology indications, including solid tumors, non-small cell lung cancer, and pancreatic cancer. Its lead diagnostic candidate, 68Ga-010, is a gallium-68 labeled integrin receptor probe currently undergoing exploratory clinical evaluation in patients with non-small cell lung cancer. Additionally, the company is developing peptide-based therapeutics for metabolic diseases, such as a GIP and GLP-1 dual agonist licensed from Sinopep.